Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data

Blood Reviews

Volumn 24, Issue 1, 2010, Pages 1-9

  Irvine, David A ^a   Heaney, Nicholas B ^a   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chronic; Drug resistance; Leukaemia; Myeloid; Protein kinase inhibitors; Stem cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; BRYOSTATIN 1; CYTARABINE; DASATINIB; IMATINIB; INTERFERON; LONAFARNIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TANESPIMYCIN;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; FLUID RETENTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

DISEASE MANAGEMENT; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 71949113371     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.11.002     Document Type: Article

References (93)

1. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
2. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
3. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
4. de Lavallade H., Apperley J.F., Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26 (2008) 3358-3363
5. Hochhaus A., Druker B., Sawyers C., et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111 (2008) 1039-1043
6. Kantarjian H., O'Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 112 (2008) 837-845
7. Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103 (2005) 1659-1669
8. Wang L., Pearson K., Ferguson J.E., and Clark R.E. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120 (2003) 990-999
9. Iacobucci I., Rosti G., Amabile M., et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24 (2006) 454-459
10. Quintas-Cardama A., Kantarjian H., Jones D., et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113 (2009) 6315-6321
11. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
12. Cortes J., Talpaz M., O'Brien S., et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11 (2005) 3425-3432
13. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
14. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
15. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112 (2008) 4437-4444
16. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
17. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
18. Koptyra M., Falinski R., Nowicki M.O., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108 (2006) 319-327
19. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
20. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
21. Soverini S., Colarossi S., Gnani A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12 (2006) 7374-7379
22. Nicolini F.E., Corm S., Le Q.H., et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP). Leukemia 20 (2006) 1061-1066
23. Sherbenou D.W., Wong M.J., Humayun A., et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 21 (2007) 489-493
24. Willis S.G., Lange T., Demehri S., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106 (2005) 2128-2137
25. Jabbour E., Kantarjian H., Jones D., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112 (2008) 53-55
26. Khorashad J.S., de Lavallade H., Apperley J.F., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26 (2008) 4806-4813
27. Mahon F.X., Belloc F., Lagarde V., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 (2003) 2368-2373
28. Crossman L.C., Druker B.J., Deininger M.W., Pirmohamed M., Wang L., and Clark R.E. HOCT 1 and resistance to imatinib. Blood 106 (2005) 1133-1134
29. Wang L., Giannoudis A., Lane S., Williamson P., Pirmohamed M., and Clark R.E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83 (2008) 258-264
30. White D.L., Saunders V.A., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
31. Darkow T., Henk H.J., Thomas S.K., et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25 (2007) 481-496
32. Kiguchi T., Tauchi T., Ito Y., Miyazawa K., Kimura Y., and Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 33 (2009) 506-508
33. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113 (2009) 5401-5411
34. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
35. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (2008) 4022-4028
36. Dorsey J.F., Cunnick J.M., Lanehart R., et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 16 (2002) 1589-1595
37. Holyoake T.L., Jiang X., Jorgensen H.G., et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97 (2001) 720-728
38. Donato N.J., Wu J.Y., Stapley J., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64 (2004) 672-677
39. Dai Y., Rahmani M., Corey S.J., Dent P., and Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279 (2004) 34227-34239
40. Wu J., Meng F., Kong L.Y., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100 (2008) 926-939
41. Calabretta B., and Perrotti D. The biology of CML blast crisis. Blood 103 (2004) 4010-4022
42. Gaiger A., Henn T., Horth E., et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86 (1995) 2371-2378
43. Cortes J.E., Talpaz M., Giles F., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101 (2003) 3794-3800
44. Holyoake T., Jiang X., Eaves C., and Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94 (1999) 2056-2064
45. Jorgensen H.G., and Holyoake T.L. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 35 (2007) 1347-1351
46. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
47. Bellodi C., Lidonnici M.R., Hamilton A., et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119 (2009) 1109-1123
48. Kantarjian H.M., Talpaz M., O'Brien S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101 (2003) 473-475
49. Kantarjian H.M., Druker B.J., Guilhot F., et al. Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase. Blood 110 (2007) 317a [abstract 1047]
50. Marin D., Goldman J.M., Olavarria E., and Apperley J.F. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 102 (2003) 2702-2703
51. Sohn S.K., Moon J.H., Cho Y.Y., et al. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance. Leuk Lymphoma 48 (2007) 1659-1661
52. Zonder J.A., Pemberton P., Brandt H., Mohamed A.N., and Schiffer C.A. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 9 (2003) 2092-2097
53. Jabbour E., Kantarjian H.M., Jones D., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113 (2009) 2154-2160
54. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
55. Stone R.M., Kantarjian H.M., Baccarani M., et al. Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). Blood 110 (2007) 225a [abstract 734]
56. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 (2007) 3207-3213
57. Guilhot F., Apperley J., Kim D.W., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
58. Hochhaus A., Baccarani M., Deininger M., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22 (2008) 1200-1206
59. Kantarjian H., Pasquini R., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109 (2007) 5143-5150
60. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546
61. le Coutre P., Ottmann O.G., Giles F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111 (2008) 1834-1839
62. Kantarjian H.M., Giles F., Bhalla K., et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 112 (2008) [abstract 3238]
63. Gambacorti C., Cortes J., Kim D.W., et al. Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program. Blood 110 (2007) 145a [abstract 472]
64. Giles F.J., Larson R.A., Kantarjian H.M., et al. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis who are resistant or intolerant to imatinib. Blood 110 (2007) 310a [abstract 1025]
65. Guilhot F., Apperley J.F., Kim D.W., et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 110 (2007) 145a [abstract 470]
66. le Coutre P., Giles F., Hochhaus A., et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 112 (2008) [abstract 3229]
67. Bradeen H.A., Eide C.A., O'Hare T., et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108 (2006) 2332-2338
68. O'Hare T., Eide C.A., and Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110 (2007) 2242-2249
69. Cortes J., Jabbour E., Kantarjian H., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110 (2007) 4005-4011
70. Jabbour E., Kantarjian H.M., Jones D., et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112 (2008) 4839-4842
71. Quintas-Cardama A., Kantarjian H., O'Brien S., et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25 (2007) 3908-3914
72. Shah N.P., Kantarjian H.M., Kim D.W., et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26 (2008) 3204-3212
73. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
74. Singer J.B., Shou Y., Giles F., et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21 (2007) 2311-2315
75. Copland M., Hamilton A., Elrick L.J., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
76. Jorgensen H.G., Allan E.K., Jordanides N.E., Mountford J.C., and Holyoake T.L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109 (2007) 4016-4019
77. Holtz M.S., Forman S.J., and Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19 (2005) 1034-1041
78. Konig H., Holtz M., Modi H., et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22 (2008) 748-755
79. Melo J.V., and Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7 (2007) 441-453
80. Roeder I., and Glauche I. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses. J Mol Med 86 (2008) 17-27
81. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M.C., and Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12 (2006) 1181-1184
82. Michor F. Mathematical models of cancer stem cells. J Clin Oncol 26 (2008) 2854-2861
83. Holtz M., Forman S.J., and Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 67 (2007) 1113-1120
84. Jorgensen H.G., Allan E.K., Mountford J.C., et al. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Exp Hematol 33 (2005) 1140-1146
85. Jorgensen H.G., Allan E.K., Graham S.M., et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19 (2005) 1184-1191
86. Copland M., Pellicano F., Richmond L., et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111 (2008) 2843-2853
87. Huntly B.J., Shigematsu H., Deguchi K., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6 (2004) 587-596
88. Barnes D.J., and Melo J.V. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol 108 (2002) 180-202
89. Dierks C., Beigi R., Guo G.R., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14 (2008) 238-249
90. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458 (2009) 776-779
91. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351 (2004) 657-667
92. Rezvani K., Yong A.S., Mielke S., et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111 (2008) 236-242
93. Rojas J.M., Knight K., Wang L., and Clark R.E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21 (2007) 2287-2295